Status: Current Investments

Clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders.

Clinical-stage biotechnology company developing inobrodib, a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases.

Clinical-stage biotechnology company working to develop potent and versatile tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins.

Clinical-stage biotechnology company developing purpose-built therapeutics by leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology.

Clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis.

Clinical-stage biotechnology company discovering and developing novel therapies to treat immune-mediated chronic inflammatory diseases.

A full-service, digitally-powered pharmacy providing an easier, more supportive and more affordable pharmacy experience.

Commercial-stage life science company focused on manufacturing scalable single-use bioreactors and providing process development services to cell therapy clients.

Global contract development and manufacturing organization for radiotherapeutics.